Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP001382) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
Fynomer COVA 322
|
|||||
| Synonyms |
COVA322
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase II | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS035 | [1] | ||||
| Scaffold Name | Fynomer | |||||
| Scaffold Class | Non-Antibody | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| Chymase | Binder | Plaque psoriasis [ICD-11: EA90.0] | Kd: 0.9 nM | Texas A&M University | [1] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT02243787 | Click to show the Detail | |||||
| Indication | Stable Chronic Moderate-to-severe Plaque Psoriasis | |||||
| Phase | Phase I; Phase II | |||||
| Title | A Randomised, Double-blind, Sequential, Ascending Single-dose Study to Evaluate Safety, Tolerability, Biological Activity, and Systemic Exposure of?COVA322, a Bispecific TNF-alpha / IL-17A Antibody Fusion Protein, in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis | |||||
| Status | Terminated?(Safety Profile of COVA322) | |||||
| Sponsor | Covagen | |||||